MedTrace Logo

Juvenile Idiopathic Arthritis (JIA) Registry

NCT00783510 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 849

Last updated 2025-02-04

No results posted yet for this study

Summary

This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be followed in both the Humira® and Methotrexate (MTX) arms for 10 years from the enrollment date into one of the treatment arms.

Conditions

  • Juvenile Idiopathic Arthritis
  • JIA

Interventions

BIOLOGICAL

adalimumab

As prescribed by treating physician

DRUG

Methotrexate

As prescribed by treating physician

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-11
Primary Completion
2024-02-01
Completion
2024-02-01

Countries

  • United States
  • Australia
  • Austria
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Netherlands
  • Norway
  • Portugal
  • Puerto Rico
  • Slovakia
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00783510 on ClinicalTrials.gov